News

QIAGEN N.V declared the U.S FDA's approval of PMA supplement augmenting indications for use of QIAGEN's therascreen EGFR RGQ PCR kit as a diagnostic to direct the use of  Boehringer…
Read More...

Private medical technology company, Bluegrass Vascular Technologies emphasizing on developing innovating lifesaving devices and methods for vascular access asserted the enrollment of…
Read More...

Company developing intratumoral cancer immunotherapies, OncoSec Medical claimed the observations of preliminary Clinical trial study related to its OMS-1140 ImmunoPulse 1L-12 in…
Read More...

Privately-held start-up developing VasQ, Laminate Medical Technologies declared the roll- out of its FDA pivotal study in the US. VasQ is an implanted blood vessel external support…
Read More...

Cloud content management, Box declared Box GxP Validation assuring GxP compliance in the cloud thereby ensuring the Pharmaceuticals, Biotechnology and Medical Device businesses to…
Read More...

In a bid to develop contrast agents with reduced renal toxicity, Ligand Pharmaceuticals set to initiate a program to develop contrast agents with lessened renal toxicity. Enabling usage…
Read More...

Pandion Therapeutics declared the completion of a $58 million Series A financing that will be utilized to further its drug programs for autoimmune and inflammatory diseases in addition…
Read More...

A Gilead Company, Kite ventures into Clinical Trial collaboration with  Pfizer, enabling assessment of the efficacy of the investigational combination of Yescarta (axicabtagene…
Read More...

Makers of the the Prenate line of prescription prenatal vitamins, Avion Pharmaceuticals sought approval of its New Drug application for the Oral Contraceptive Balcoltra (levonorgestrel…
Read More...

Clinical stage company, Relmada Therapeutics into developing novel therapies for treating Centralnervous system diseases obtained global rights to develop and market dextromethadone…
Read More...

Molecule discovery specialist X-Chem, proclaimed a remarkable extension of their present drug discovery collaboration with AstraZeneca. The agreement focuses on the synthesis and…
Read More...

Eiger Biopharmaceuticals displaying forte in development and commercialization of targeted therapies for rare diseases declared negative results for Phase 2 LIBERTY study in pulmonary…
Read More...

Marina Biotech, a biopharmaceutical company committed to the development and commercialization of advanced therapeutics for hypertension, arthritis, pain and oncology embarked on a…
Read More...

Digital patient decision support platform, WiserCare declared the appointment of Daniel J. Castillo as its Chief Executive Officer.  He brings with him profound experience and knowledge…
Read More...

A biotech company that designs and develops virus-based  immunotherapies, Transgene confirms dosing the first patient in  a Phase 1 Clinical Trial in China, evaluating T101, therapeutic…
Read More...

Ipsen bio-pharmaceuticals set to present five new sub-analyses of the pivotal Phase 3 NAPOLI-1 trial at this year's American Society of Clinical Oncology’s Gastrointestinal Cancer…
Read More...

US Food and Drug Administration (FDA) has assured priority review of Novartis supplemental Biological License Application (sBLA) for Kymriah suspension for intravenous infusion,…
Read More...

U.S FDA clears OBI Pharma's investigational new drug (IND) application for a Phase 1 study of a monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen…
Read More...

BioLineRx, committed to oncology and immunology declared partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study. The study reveals that BL-8040 increases…
Read More...

Neurim Pahrmaceuticals and BIOCODEX undertake a license agreement that enlists the fact that BIOCODEX will possess the exclusive marketing rights to market Neurim's Rx paediatric…
Read More...